

Special Issue

Genetics of Alzheimer's Disease: Clues for Early Diagnosis and Intervention

Message from the Guest Editor

Alzheimer's disease (AD) is the most common neurodegenerative disorder, affecting over 55 million people, and this number is expected to increase exponentially with the increasing aging population worldwide. Some large scale genetic analysis trying to elucidate the cause of the AD has been carried out; however, the causes remain unclear. In this Special Issue, we will focus on the genetic findings on AD which may facilitate early diagnosis by identifying the high-risk groups or those with faster cognitive decline. Studies related to genetic markers, genome-wide association studies, gene expression analysis, RNA-Seq and bioinformatic analysis on AD are welcome.

Guest Editor

Dr. Suk Ling Ma

Department of Psychiatry, Chinese University of Hong Kong, Shatin, Hong Kong

Deadline for manuscript submissions

closed (15 February 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 3.1
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/113164

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 3.1
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))